

INSTITUTE-UNIVERSITY INSTITUTE OF ENGINEERING

ACADEMIC UNIT-II

Computer Science Engineering
Subject Name-Biology For Engineers
Subject Code- 20SZT148

CORONA VIRUS

DISCOVER. LEARN. EMPOWER



Course Outcome


CO Number	Title	Level
CO1	It gives an idea about the about the basic cell biology.	Understanding
CO2	It deals with the idea of uses of biology in engineering.	Understanding
CO3	It provide knowledge about the uses of softwares in biology field.	Remembering







BIOLOGY FOR ENGINEERS



Medical instruments, Biosensors, Biosensors, Recombinant DNA technology and Immunology (UNIT-2)

Enzymes,
Nervous
system,Bioinfo
rmatics and
Disesaes
(UNIT-3)





• Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans.



• Coronaviruses are zoonotic, meaning they are transmitted between animals and people. Detailed investigations found that SARS-CoV was transmitted from civet cats to humans and MERS-CoV from dromedary camels to humans. Several known coronaviruses are circulating in animals that have not yet infected humans.



COVID-19 or SARS-CoV-2

• SARS-CoV-2 refers to severe acute respiratory syndrome coronavirus 2 which was announced by ICTV (International Committee on Taxonomy of Viruses) as the name of the new virus on 11 February 2020.

• This name was chosen because the virus is genetically related to the coronavirus responsible for the SARS outbreak of 2003. While related, the two viruses are different.



COVID-19 is the name of this new disease announced on 11 February 2020, following guidelines previously developed with the World Organisation for Animal Health (OIE) and the Food and Agriculture Organization of the United Nations (FAO).



Clinical Features:

Incubation period: 1-27 days

Recovery time: 3 weeks to 6 weeks

Frequently reported signs and symptoms of patients include:

- fever (77–98%)
- cough (46%–82%)
- myalgia or fatigue (11-52%)
- shortness of breath (3-31%)

less commonly reported respiratory symptoms include <u>sore throat, headache,</u> <u>cough with sputum production and/or hemoptysis</u>.

https://image.slidesharecdn.com/covid-19-200315202203/95/coronavirus-disease-covid19-4-638.jpg?cb=1584305413





Clinical Features:

- Incubation period: 1-27 days
- Recovery time: 3 weeks to 6 weeks
- Frequently reported signs and symptoms of patients include:
- fever (77–98%)
- cough (46%–82%)
- myalgia or fatigue (11–52%)
- shortness of breath (3-31%) less commonly reported respiratory symptoms include sore throat, headache, cough with sputum production and/or hemoptysis.





Diagnosis:

- 1. Travel history to endemic countries like (China, Iran & Italy)
- 2. CBC (leukopenia, seen in 30% to 45% of patients, and lymphocytopenia, seen in 85% of the patients)
- 3. Chest X-Ray (cheaper & easier with 60% sensitivity)
- 4. PCR (30%-70% sensitivity)
- 5. Chest CT Scan (95% sensitivity, low specificity)
- 6. IgM/IgG combo test for COVID-19





Treatment:

- 1. Mild cases: Supportive treatments (Antihistamine & Analgesics)
- 2. Moderate cases: a. Oseltamivir (150 mg BID for 5 days) b. Hydroxychloroquine, Chloroquine (500 mg BID for 14 days) or Ribavirin (for 5 days)
- 3. Severe cases: a. Oseltamivir (150 mg BID for 5 days) b. Kaletra (Lopinavir/Ritonavir) (for 5 days) c. Hydroxychloroquine, Chloroquine (500 mg BID for 14 days) or Ribavirin (for 5 days)
- 4. Critical cases: a. Oseltamivir (150 mg BID for 5 days) b. Kaletra (Lopinavir/Ritonavir) (for 5 days) c. Ribavirin (for 5 days) d. Hydroxychloroquine or Chloroquine (for 14 days) Investigational therapies: Favilavir (Favipiravir) Remdesivir Teicoplanin Tocilizumab



CONCLUSION

Till now we have discuss:

- Corona virus
- Cause of virus
- Clinical features of
- Diagnosis
- Treatment





REFERENCES

- C.B.Powar, 2010.Cell Biology.5th Ed,Himalyan Publishing House.
- Leshie Cromwell, Fred.J. Weibell and Erich.A.Pfeiffer. 2003. Biomedical instrumentation and measurements. 2nd edition, PHI.
- John G. Webster 1998. Medical Instrumentation: Applications and Design, 3rd edition, Jon Wiley and Sons, New York.
- Jeremy M. Berg, John L. Tymoczko and Lubert Stryer. 2006. "Biochemistry," 6th Ed. W.H. Freeman and Co. Ltd.
- Robert Weaver. 2012 "Molecular Biology," 5th Edition, MCGraw-Hill.
- Jon Cooper, , 2004. "Biosensors A Practical Approach" Bellwether Books.
- Martin Alexander, 1994 "Biodegradation and Bioremediation," Academic Press.







For queries

Email: subject_code_2020@gmail.com